Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Current Assets Current Deferred Revenue Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Investments Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Non-Current Deffered Revenue Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares

Cash Flow Statement

Daily Values

Growth Metrics

Akebia Therapeutics (AKBA) Long-Term Deferred Tax (2018 - 2019)

Akebia Therapeutics has reported Long-Term Deferred Tax over the past 2 years, most recently at $109.4 million for Q4 2019.

Quarterly Long-Term Deferred Tax fell 3.04% to $109.4 million in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $109.4 million through Dec 2019, down 3.04% year-over-year, with the annual reading at $109.4 million for FY2019, 3.04% down from the prior year.
Long-Term Deferred Tax was $109.4 million for Q4 2019 at Akebia Therapeutics, down from $112.8 million in the prior quarter.
Over five years, Long-Term Deferred Tax peaked at $112.8 million in Q4 2018 and troughed at $109.4 million in Q4 2019.